Pulmonary embolism- monitoring of anticoagulation therapy at Transfusion Center Maribor in 2011
Abstract
Background: Pulmonary embolism is a common and often fatal disease. Mortality can be reduced with prompt diagnosis and therapy. PE is caused by obstruction of the pulmonary artery or its branches by thrombus. Diagnois is based on clinical exam, CT scan, perfusion scintigraphy, and laboratory tests. There are many risk factors for venous thromboembolism (VTE) and PE. Almost all hospitalized patients have one risk factor for VTE and about 40 % have three or more risk factors. Methods: In our center, patients with previous PE are controlled after hospitalization.INR is measured from venous citrate blood using Siemens BCS instrument. Patients’ data were obtained from hospital program Medis. Results: In the past year, 373 patients were controlled because of PE. Patients taking coumarin in the last year because of other reasons, mechanical valves, atrial fibrillation, or who had PE more than 15 years ago were excluded from the study. After this exclusion, we searched data for 284 patients. Summary/conclusion: Among 284 patients controlled in our center there were 174 (61 %) women and 110 (39 %) men. 269 (95 %) were taking warfarin, only 15 (5 %) were taking acenocoumarol. 71 ( 25 % ) of patients have already had TE (thromboembolism) in the past, 14 (5 %) of them had a PE recurrence.Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
